Biofluidica, Inc.
Other Technology · San Diego, California
Biofluidica, Inc. is a other technology company based in San Diego, California, incorporated in 2013. It has reported $18.7 million raised across 8 Form D filings with the SEC, most recently in 2021.
CELL - AND EXOSOME - BASED LIQUID BIOPSY Cell- and exosome-based liquid biopsy is now here. As a liquid biopsy company, BioFluidica has created the future of liquid biopsy by creating LiquidScan®. *LiquidScan isolates rare cells and exosomes, making diagnostics possible for cell- and exosome-based liquid biopsy. *LiquidScan combines cutting-edge microfluidics, advanced immunoaffinity chemistries, automation hardware,
| Date | Round | Amount | Raised to date | Lead investor | Source |
|---|---|---|---|---|---|
| 2021-12-02 | — | $3.5M | $18.7M | SEC Form D | |
| 2019-12-05 | —+1 amd | $6.0M | $15.1M | SEC Form D | |
| 2018-09-13 | —+1 amd | $3.0M | $9.1M | SEC Form D | |
| 2017-07-27 | — | $4.1M | $6.1M | SEC Form D | |
| 2016-04-18 | —+1 amd | $2.0M | $2.0M | SEC Form D |
SEC rows are Form D filings, where the amount is what was actually sold and amendments update a round rather than adding one. Press rows are split between company-issued releases or wires and editorial or third-party coverage. The total is therefore a floor: a round nobody reported is a round we cannot see. A buyout or control change appears in the timeline but is never added to the total: that money goes to shareholders, not into the company.
Form D is the notice a company files with the SEC when it sells securities without registering them. It reports the amount sold, not a valuation. Figures here are what the filing says. Where a filing is silent, the field is left blank rather than estimated. “Total raised” adds press-reported rounds that never appear in a filing, so it is a floor rather than an audited sum: press amounts are the figures the company announced, and a round nobody reported is a round we cannot see.